VX-809
936727-05-8
99%
2026-07-05
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName VX-809 Cat No CEI-0253 Description VX-809 can inhibit CFTR with IC 50 of 100 nM. CAS No 936727-05-8 Molecular Weight 452.41 Purity >99% Storage 2 years at -20centigrade Powder Targets CFTR Molecular Formula C24H18F2N2O5 Chemical Name 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Solubility DMSO 91 mg/mL Water In vitro VX-809 is a CFTR corrector that was advanced into clinical development for the treatment of cystic fibrosis. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC(50), 81 +/- 19 nM), a level associated with mild CF in patients with less disruptive CFTR mutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability. category Inhibitors(c1514) cas_num 936727-05-8 Basic Info-
Product Name:
Lumacaftor
Other Name:Benzoic acid,3-[6-[[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]-;3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid;VRT 826809;VX 809;Lumacaftor;3-[6-[[[1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methylpyridin-2-yl]benzoic acid;1220975-12-1
CAS No.:936727-05-8
Molecular Formula:C24H18F2N2O5
InChIKeys:InChIKey=UFSKUSARDNFIRC-UHFFFAOYSA-N
Molecular Weight:452.4069264
Exact Mass:452.41
Categories:
Characteristics-
PSA:
97.8
XLogP3:4.4
Density:1.5±0.1 g/cm3
Boiling Point:653.013°C at 760 mmHg
Flash Point:348.7±31.5 °C
Refractive Index:1.670
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 3, Oral
Acute toxicity - Category 3, Dermal
Serious eye damage, Category 1
Reproductive toxicity, Category 2
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H372 Causes damage to organs through prolonged or repeated exposure
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P203 Obtain, read and follow all safety instructions before use.
Response P301+P316 IF SWALLOWED: Get emergency medical help immediately.
P321 Specific treatment (see ... on this label).
P330 Rinse mouth.
P302+P352 IF ON SKIN: Wash with plenty of water/...
P316 Get emergency medical help immediately.
P361+P364 Take off immediately all contaminated clothing and wash it before reuse.
P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P317 Get medical help.
P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product